Arena Pharmaceuticals, Inc. News Releases http://invest.arenapharm.com/ Arena Pharmaceuticals, Inc. News Releases en Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-presence-digestive-disease-week-ddw - ELEVATE UC Phase 3 global program site initiations - New data for both etrasimod and olorinab SAN DIEGO , May 17, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in Fri, 17 May 2019 08:30:00 -0400 Arena Pharmaceuticals, Inc. News Releases 19356 Arena Pharmaceuticals to Participate in Upcoming Investor Conferences http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-participate-upcoming-investor-1 SAN DIEGO , May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: UBS Global Healthcare Conference on Monday, May 20 , at 8:30 AM EDT in New York City RBC Capital Mon, 13 May 2019 08:30:00 -0400 Arena Pharmaceuticals, Inc. News Releases 19336 Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-provides-corporate-update-and-reports-18 - Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis - Multiple first- or best-in-class therapeutics, strong leadership team and liquidity position of approximately $1.3 billion SAN DIEGO , May 8, 2019 /PRNewswire/ -- Arena Wed, 08 May 2019 16:01:00 -0400 Arena Pharmaceuticals, Inc. News Releases 19316 Arena Pharmaceuticals to Release First Quarter 2019 Financial Results and Provide Corporate Update on May 8 http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-release-first-quarter-2019-financial SAN DIEGO , May 1, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live Wed, 01 May 2019 08:30:00 -0400 Arena Pharmaceuticals, Inc. News Releases 19311 Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10 http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-present-18th-annual-needham-healthcare SAN DIEGO , April 3, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:00 PM Wed, 03 Apr 2019 08:30:00 -0400 Arena Pharmaceuticals, Inc. News Releases 19286 Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-presented-new-phase-2-data-etrasimod-and SAN DIEGO , March 8, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to Fri, 08 Mar 2019 08:30:00 -0500 Arena Pharmaceuticals, Inc. News Releases 19271 Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-provides-corporate-update-and-reports-17 - Etrasimod demonstrated clinical response and durable, long-term clinical remission and favorable long-term safety and tolerability in an open-label extension trial - Completed global license agreement with United Therapeutics for ralinepag, received $800M upfront payment, and eligible to receive Tue, 26 Feb 2019 16:01:00 -0500 Arena Pharmaceuticals, Inc. News Releases 19251 Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27 http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-present-8th-annual-svb-leerink-global SAN DIEGO , Feb. 21, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 Thu, 21 Feb 2019 08:30:00 -0500 Arena Pharmaceuticals, Inc. News Releases 19241 Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2018 Financial Results and Provide Corporate Update on February 26 http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-announce-fourth-quarter-and-full-year-2018 SAN DIEGO , Feb. 20, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its fourth quarter and full-year 2018 financial results on Tuesday, February 26, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live webcast to Wed, 20 Feb 2019 16:01:00 -0500 Arena Pharmaceuticals, Inc. News Releases 19236 Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress http://invest.arenapharm.com/news-releases/news-release-details/arena-pharmaceuticals-presents-preclinical-and-early-clinical SAN DIEGO , Feb. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB 2 ) in Thu, 07 Feb 2019 16:30:00 -0500 Arena Pharmaceuticals, Inc. News Releases 19216